RGEN
Repligen Corporation
NasdaqGSUSDEQUITY
DELAYED
Last price
181.00
▲ 0.71 (0.39%)
MARKET · —
Price
Open
182.07
Prev close
180.29
Day high
182.43
Day low
175.75
Volume
1.09M
Market cap
—
P/E (TTM)
—
52W range
100.99 – 188.73
Trailing performance
Returnvs SPY
1W
+8.57%
+9.9%
1M
+31.64%
+27.9%
3M
+59.77%
+56.7%
6M
+33.50%
+22.4%
YTD
+10.54%
-1.7%
1Y
+49.00%
+29.0%
3Y
+7.83%
-66.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
170.09
+6.41% from price
SMA 20
159.10
+13.85% from price
SMA 50
146.95
+23.26% from price
SMA 100
133.33
+35.75% from price
SMA 200
140.61
+28.82% from price
EMA 12
168.56
+7.38% from price
EMA 26
159.02
+13.82% from price
EMA 50
149.59
+21.00% from price
RSI (14)
76.2
Overbought
MACD (12,26,9)
9.54
Hist 1.78
ATR (14)
7.17
3.96% of price
Realised vol 30D
48.6%
Annualised
Bollinger upper
186.38
20, 2σ
Bollinger lower
131.82
20, 2σ
50 / 200 cross
Golden
146.95 vs 140.61
Trend bias
Above 200
+28.82%
Risk profile
Beta vs SPY
1.23
More volatile than market
Correlation to SPY
0.34
Loosely linked
Realised vol 30D
48.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-40.3%
Peak to trough
Max drawdown 5Y
-68.3%
Peak to trough
ATR 14
7.17
3.96% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
3 Hyped Up Stocks We Keep Off Our Radar
StockStory · 1d ago
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos
Zacks · 2d ago
Repligen (RGEN) Stock Could Be 1% Overvalued Despite Its 45% Run
Simply Wall St. · 2d ago
These Two Biotech Stocks Recorded Fresh Milestones Today – What’s Driving Today’s Gains?
Stocktwits · 3d ago
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
Zacks · 3d ago
MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up
Zacks · 4d ago
UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label
Zacks · 4d ago
Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks
StockStory · 5d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.